28-Mar-2025
TD Cowen Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
TipRanks (Sun, 30-Mar 10:05 AM ET)
SA Asks: What are the best large-cap cardiology stocks right now?
Seeking Alpha News (Sat, 29-Mar 12:00 PM ET)
Abbott Laboratories (ABT) Receives a Buy from Citi
TipRanks (Fri, 28-Mar 6:48 AM ET)
HHS plans 10,000 job cuts with FDA, CDC, Medicare affected (update)
Seeking Alpha News (Thu, 27-Mar 9:15 AM ET)
Seeking Alpha News (Thu, 27-Mar 9:05 AM ET)
PRNewswire (Thu, 27-Mar 9:00 AM ET)
RFK Jr. reportedly plans 10,000 job cuts in HHS with FDA, CDC, Medicare affected
Seeking Alpha News (Thu, 27-Mar 8:22 AM ET)
Abbott Hosts Conference Call for First-Quarter Earnings
PRNewswire (Wed, 26-Mar 9:00 AM ET)
PRNewswire (Mon, 24-Mar 9:00 AM ET)
Business Wire (Thu, 13-Mar 4:05 PM ET)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Abbott Laboratories trades on the NYSE stock market under the symbol ABT.
As of March 28, 2025, ABT stock price declined to $130.82 with 6,027,181 million shares trading.
ABT has a beta of 0.19, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.02 to the broad based SPY ETF.
ABT has a market cap of $226.90 billion. This is considered a Mega Cap stock.
Last quarter Abbott Laboratories reported $11 billion in Revenue and $1.34 earnings per share. This fell short of revenue expectation by $-56 million and met earnings estimates .
In the last 3 years, ABT traded as high as $141.23 and as low as $89.67.
The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.
ABT has outperformed the market in the last year with a price return of +17.1% while the SPY ETF gained +7.6%. ABT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +14.3% and +3.2%, respectively, while the SPY returned -6.3% and -1.0%, respectively.
ABT support price is $129.21 and resistance is $133.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT shares will trade within this expected range on the day.